Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 17, 2026
ACR Appropriateness Criteria® Indolent Lung Cancer.
Journal: Journal of the American College of Radiology : JACR
Published: June 29, 2026
Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 09, 2026
Current Surgical Perspectives for Pleural Mesothelioma.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 10, 2026
ASO Visual Abstract: Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: Four-Year National Perspective.
Journal: Annals of surgical oncology
Published: March 10, 2026
Margin-negative resection and long-term survival following robot-assisted thymectomy for thymoma: A tumor size stratified analysis.
Journal: JTCVS open
Published: October 27, 2025
Treatment of Multifocal Disease: When Is Intervention Really Needed?
Journal: Surgical oncology clinics of North America
Published: October 19, 2025
Two-surgeon esophagectomy: An emerging paradigm.
Journal: The Journal of thoracic and cardiovascular surgery
Published: October 16, 2025
Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: 4-Year National Perspective.
Journal: Annals of surgical oncology
Published: October 01, 2025
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 10, 2025
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 11, 2025
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.
Journal: The Journal of thoracic and cardiovascular surgery
Published: June 09, 2025
Last Updated: 09/26/2026